MITI Micromet, Inc. featured news, full reports, and detailed charts
Micromet, Inc. (MITI) Wrap Up:
We are a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Three of our antibodies are currently in clinical trials, while the remainder of our product pipeline is in preclinical development. MT103, also known as MEDI-538, the most advanced antibody in our product pipeline developed using our BiTE® antibody technology platform, is being evaluated in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin’s lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient’s own cytotoxic T cells, considered the most powerful “killer cells” of the human immune system, to eliminate cancer cells. We are developing MT103 in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f14%2f0000950133-08-001064.html#FIS_BUSINESS"Micromet, Inc. (MITI:NASDAQ)
Snapshot of Micromet, Inc. (MITI)
|
OPEN
$7.08
|
PREVIOUS CLOSE
$7.13
|
|
|
DAY HIGH
$7.20
|
DAY LOW
$6.62
|
|
|
52 WEEK HIGH
09/17/09 - $8.48
|
52 WEEK LOW
03/2/09 - $2.25
|
|
|
MARKET CAP
476.0M
|
AVERAGE VOLUME 3 mo
326.1K
|
|
|
DILUTED EPS TTM
$-0.71
|
SHARES OUTSTANDING
69.0M
|
|
|
MITI Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
related news
Some familiar big-cap stocks, such as Genentech, as well as a host of promising small caps head the list of biotech prospects
MITI Top Compensated Officers
Executives, Board Directors
Key developments for Micromet, Inc. (MITI)
Micromet, Inc. expected to Report Fiscal Year 2009 Results on March 1, 2010. This event was calculated by Capital IQ (Created on November 13, 2009).
Micromet, Inc. - Conference Presentation Calls
Micromet Inc. announced unaudited consolidated financial results for the three months and nine months ended September 30, 2009. For the three months, the company recognized total revenues of $4.0 million, compared to $7.0 million for the same period in 2008. Loss from operations for the three months ended September 30, 2009 was $13.1 million, compared to a loss from operations of $6.3 million for the same period in 2008. For the three months ended September 30, 2009, the company reported a net loss of $19.9 million, or a loss of $0.32 per basic and diluted common share, compared to a net loss of $12.9 million, or $0.31 per basic and diluted common share for the same period in 2008. The net loss for the three months ending September 30, 2009 includes a non-cash charge of $6.4 million, reflecting an increase during the quarter in the fair value of warrants issued in connection with a private placement transaction in 2007. The company recorded a $6.8 million non-cash charge for this item in the third quarter of 2008. For the nine months ended September 30, 2009, the recognized total revenues of $16.4 million, compared to $21.4 million for the same period in 2008. Loss from operations for the nine months ended September 30, 2009 was $25.7 million, compared to a loss from operations of $19.6 million for the same period in 2008. For the nine months ended September 30, 2009, the company reported a net loss of $34.2 million, or a loss of $0.62 per basic and diluted common share, compared to a net loss of $27.4 million, or $0.67 per basic and diluted common share, for the same period in 2008. The net loss for the nine months ended September 30, 2009 includes a non-cash charge of $8.2 million, reflecting an increase during the period in the fair value of warrants issued in connection with a private placement transaction in 2007, in addition to the $2.6 million patent impairment charge. Micromet recorded an $8.5 million non-cash charge for the change in the fair value of the warrants in the first nine months of 2008. Net cash used in operating activities was $13.1 million for the nine months ended September 30, 2009 compared to $8.7 million used in operating activities for the same period in 2008. The company announced a one-time non-cash patent impairment charge of $2.6 million. For the nine months, the company reported a one-time non-cash patent impairment charge of $2.6 million.
MITI Competitors
| Company | Last | Change |
| Generex Biotechnology Corp | $0.50 USD | -0.01 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | MITI | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 20.0x |
|
| Price/Book | 5.6x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 16.9x |
|
|
MITI |
||
MITI transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
